These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 10427507)

  • 1. [Pathogenesis of malignant melanoma. Molecular biology aspect].
    Waldmann V; Bock M; Jäckel A; Deichmann M; Dockendorff K; Näher H
    Hautarzt; 1999 Jun; 50(6):398-405. PubMed ID: 10427507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations of p16 and p15 tumor suppressor genes and replication errors contribute independently to the pathogenesis of sporadic malignant melanoma.
    Matsumura Y; Nishigori C; Yagi T; Imamura S; Takebe H
    Arch Dermatol Res; 1998 Apr; 290(4):175-80. PubMed ID: 9617435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ultraviolet damage, DNA repair and vitamin D in nonmelanoma skin cancer and in malignant melanoma: an update.
    Reichrath J; Rass K
    Adv Exp Med Biol; 2014; 810():208-33. PubMed ID: 25207368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression.
    Piccinin S; Doglioni C; Maestro R; Vukosavljevic T; Gasparotto D; D'Orazi C; Boiocchi M
    Int J Cancer; 1997 Feb; 74(1):26-30. PubMed ID: 9036865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression.
    Reed JA; Loganzo F; Shea CR; Walker GJ; Flores JF; Glendening JM; Bogdany JK; Shiel MJ; Haluska FG; Fountain JW
    Cancer Res; 1995 Jul; 55(13):2713-8. PubMed ID: 7796391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impaired processing of DNA photoproducts and ultraviolet hypermutability with loss of p16INK4a or p19ARF.
    Sarkar-Agrawal P; Vergilis I; Sharpless NE; DePinho RA; Rünger TM
    J Natl Cancer Inst; 2004 Dec; 96(23):1790-3. PubMed ID: 15572761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. UV damage and DNA repair in malignant melanoma and nonmelanoma skin cancer.
    Rass K; Reichrath J
    Adv Exp Med Biol; 2008; 624():162-78. PubMed ID: 18348455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression and significance of p53, rb, p21/waf-1, p16/ink-4a, and PTEN tumor suppressors in canine melanoma.
    Koenig A; Bianco SR; Fosmire S; Wojcieszyn J; Modiano JF
    Vet Pathol; 2002 Jul; 39(4):458-72. PubMed ID: 12126149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melanoma genetics: an update with focus on the CDKN2A(p16)/ARF tumor suppressors.
    Piepkorn M
    J Am Acad Dermatol; 2000 May; 42(5 Pt 1):705-22; quiz 723-6. PubMed ID: 10775844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular mechanisms of photocarcinogenesis.
    Matsumura Y; Ananthaswamy HN
    Front Biosci; 2002 Apr; 7():d765-83. PubMed ID: 11897559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular genetics of human malignant melanoma.
    Albino AP; Fountain JW
    Cancer Treat Res; 1993; 65():201-55. PubMed ID: 8104022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular and genetic mechanisms in melanoma.
    Gruber F; Kastelan M; Brajac I; Saftić M; Peharda V; Cabrijan L; Stanić Zgombić Z; Simonić E
    Coll Antropol; 2008 Oct; 32 Suppl 2():147-52. PubMed ID: 19138018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of expression of the p16INK4/CDKN2 gene in cutaneous malignant melanoma correlates with tumor cell proliferation and invasive stage.
    Talve L; Sauroja I; Collan Y; Punnonen K; Ekfors T
    Int J Cancer; 1997 Jun; 74(3):255-9. PubMed ID: 9221801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Molecular biology of familial cases of human melanoma].
    Kit OI; Vodolazhsky DL; Timoshkina NN; Przhedetsky YV; Khokhlova OV
    Vopr Onkol; 2015; 61(6):889-97. PubMed ID: 26995975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Genetic bases of cutaneous tumors].
    Basset-Séguin N; Dereure O; Guillot B
    Ann Dermatol Venereol; 1995; 122(4):217-25. PubMed ID: 8526416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Genetic counseling and DNA testing in patients with increased risks for malignant melanoma].
    Itin PH; Fistarol SK
    Ther Umsch; 2003 Aug; 60(8):469-72. PubMed ID: 14502854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. UV-Induced Molecular Signaling Differences in Melanoma and Non-melanoma Skin Cancer.
    Liu-Smith F; Jia J; Zheng Y
    Adv Exp Med Biol; 2017; 996():27-40. PubMed ID: 29124688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of human tissue to assess the oncogenic activity of melanoma-associated mutations.
    Chudnovsky Y; Adams AE; Robbins PB; Lin Q; Khavari PA
    Nat Genet; 2005 Jul; 37(7):745-9. PubMed ID: 15951821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncogenes and tumor suppressor genes in cutaneous malignant melanoma.
    Albino AP; Fountain JW
    Photochem Photobiol; 1996 Apr; 63(4):412-8. PubMed ID: 8934752
    [No Abstract]   [Full Text] [Related]  

  • 20. [Genetic basis of malignant melanoma].
    Drewa G; Powierska-Czarny J
    Postepy Hig Med Dosw; 1998; 52(4):367-80. PubMed ID: 9780757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.